Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05158621 · ClinicalTrials.gov registry record
A Screening Study Targeting Tumor-specific Antigens
A clinical trial, sponsored by Gritstone bio.
- Completed
- Registry status
- 22
- Enrollment target
NCT05158621 is a clinical trial that has completed, run by Gritstone bio. The registered enrollment target is 22 participants.
The verdict
NCT05158621 has completed, sponsored by Gritstone bio.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of metastatic, microsatellite-sable colorectal cancer (MSS-CRC) sponsored by Gritstone bio. This may include the manufacturing of an individualized vaccine, which involves neoantigen prediction and generating a vaccine targeting neoantigens.
Interventions
- PROCEDURE blood collection for research (next generation sequencing [NGS])
- PROCEDURE blood collection for research (HLA typing)
- PROCEDURE blood collection for research (circulating tumor DNA [ctDNA])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2022-08-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05158621
The ClinicalTrials.gov registry entry for NCT05158621 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gritstone bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which blood collection for research (next generation sequencing [NGS]) is the first listed.
NCT05158621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05158621 about?
NCT05158621 is a clinical study titled "A Screening Study Targeting Tumor-specific Antigens". The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of metastatic, microsatellite-sable colorectal cancer (MSS-CRC) sponsored by ...
What is the current status of trial NCT05158621?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2021-12-14. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT05158621?
The interventions under investigation include: blood collection for research (next generation sequencing [NGS]) (PROCEDURE), blood collection for research (HLA typing) (PROCEDURE), blood collection for research (circulating tumor DNA [ctDNA]) (PROCEDURE).
Who is sponsoring clinical trial NCT05158621?
This trial is sponsored by Gritstone bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.